18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03051581

Enrollment

Registered

2017-02-13

Start date

2017-03-01

Completion date

2020-12-31

Last updated

2017-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, T-Cell, Peripheral

Keywords

Lymphoma, T-Cell, Peripheral, Positron-Emission Tomography, Prognosis

Brief summary

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression

Detailed description

In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in PTCL.

Interventions

DEVICE18F-FDG PET/ CT

18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 80 Years

Healthy volunteers

Inclusion criteria

* newly diagnosed PTCL * treated using an anthracycline-containing regimen * minimal follow-up at 6 months after the completion of first-line treatment * complete medical history and clinicopathological data

Exclusion criteria

* secondary malignant disease * serious infection or inflammation (e.g., HIV) * primary central nervous system lymphoma * hepatic or renal dysfunction.

Design outcomes

Primary

Measure	Time frame
3 year progression-free survival	up to 3 years after initial diagnosis

Countries

China

Contacts

Primary ContactXuejuan Wang, MD

xuejuan_wang@hotmail.com86 10-88196364

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026